• Careers
  • Healthcare Professionals
  • Patient Centricity
  • Suppliers
  • language EN
menu
close
  • language EN
logo-image
  • About chevron_right
    • About
    • Leadership
    • Corporate Strategic Plan (CSP)
    • Our History
    • Patient Centricity chevron_right
      • Patient Centricity
      • Patient Partnerships
      • Medical Intelligence and Patient Insights
      • Patient Insights and Solutions
      • Behavioral Science Consortium
      • Culture and Integration
    • Digital Transformation
    • Astellas Integrated Report
    • Astellas Code of Conduct
    • Corporate Governance chevron_right
      • Corporate Governance
      • Risk Management
    • Ethics and Compliance chevron_right
      • Ethics and Compliance
      • Global Ethics and Compliance Structure
      • Ethics and Compliance Focus Areas
      • Ethics and Compliance Program Elements
      • Astellas' Culture of Integrity
    • Policies and Position Statements
    • Privacy Center
    • Transparency Center
  • Science chevron_right
    • Science
    • Research and Development chevron_right
      • Research and Development
      • Primary Focuses chevron_right
        • Primary Focuses
        • Blindness and Regeneration
        • Genetic Regulation
        • Immuno-Oncology
        • Targeted Protein Degradation
      • Drug Discovery Capabilities
      • Pipeline
      • Clinical Trials
      • External Funding chevron_right
        • External Funding
        • Research
        • Medical Education
        • Congress Attendance for HCPs
        • Charitable Funding
      • Open Innovation chevron_right
        • Open Innovation
        • SakuLab-TsuKuba
        • SakuLab-Cambridge
        • TME iLab
    • Manufacturing and Supply
    • Medicines and Disease Areas chevron_right
      • Medicines and Disease Areas
      • Medicines by Location
      • Oncology
      • Ophthalmology
      • Urology
      • Immunology
      • Women's Health
    • Digital Health Solutions​ chevron_right
      • Digital Health Solutions​
      • Rx+ Business Accelerator
      • HealthX
  • Partnering chevron_right
    • Partnering
    • Examples and Testimonials
    • Get in Touch
    • Areas of Interest
    • Potential Acquisition of Astellas R&D Programs
  • Investors chevron_right
    • Investors
    • Stock and Analyst Information
    • IR Library
    • For Individual Investors
    • Financial Results Library
    • Investor Relations Contact
    • Electronic Public Notices
  • Sustainability chevron_right
    • Sustainability
    • ESG chevron_right
      • ESG
      • ESG Data – Environment
      • ESG Data – Social
      • ESG Data – Governance
    • Access to Health chevron_right
      • Access to Health
      • Access to Medicines
      • Global Health and Social Impact
      • Astellas Global Health Foundation
    • Astellas and Society chevron_right
      • Astellas and Society
      • Our People
      • Human Rights
      • Sustainability in Business Practice
    • The Environment chevron_right
      • The Environment
      • EHS Management and Disclosures based on TCFD
      • Environmental Action Plan and Compliance
      • Environmental Accounting and Reporting Methods
  • Media chevron_right
    • Media
    • News
    • Our Stories
    • Media Library
    • Local News

  • Careers
  • Healthcare Professionals
  • Patient Centricity
  • Suppliers
  • Contact Us
  • search
    • Clear

      Quick Links

      • east Astellas Media
      • east Clinical Trials
    • Contact Us
    menu
    Close
    • arrow_back Back
    • Close close
    • Contact Us
    close
    You are about to leave this site.

    You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.

     

    Would you like to continue?

    • arrow_right_alt Cancel arrow_right_alt
    • arrow_right_alt Yes, Continue arrow_right_alt
    • Close close
    Choose Language
    • English
    • Japanese
    Interior of Astellas China’s office, where teams develop innovative therapies with integrity and patient-first focus.

    China newsroom

    Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.

    Latest news
    威络益@(佐妥昔单抗)联合疗法全国首批处方落地 为局部晚期不可切除或转移性胃或胃食管交界处腺癌患者一线治疗 带来全新精准治疗方案
    Jun 30, 2025

    Read more 威络益@(佐妥昔单抗)联合疗法全国首批处方落地 为局部晚期不可切除或转移性胃或胃食管交界处腺癌患者一线治疗 带来全新精准治疗方案

    安斯泰来与信诺维就临床研究阶段靶向CLDN18.2的新型抗体偶联药物XNW27011达成独家许可协议
    May 30, 2025

    Read more 安斯泰来与信诺维就临床研究阶段靶向CLDN18.2的新型抗体偶联药物XNW27011达成独家许可协议

    安斯泰来在2025年美国临床肿瘤学会(ASCO)年会上展示其在肿瘤治疗领域中的潜力
    May 19, 2025

    Read more 安斯泰来在2025年美国临床肿瘤学会(ASCO)年会上展示其在肿瘤治疗领域中的潜力

    All local news

    Discover more

    Media contacts

    Return to global media homepage

    China

    Follow China news

    Logo_txt
    menu
    close

    Navigate

    • About
    • Science
    • Partnering
    • Investors
    • Sustainability
    • Media

    Explore

    • Our Medicines
    • Pipeline
    • Careers

    Follow Us

    • LinkedIn open_in_new
    • YouTube open_in_new

    Contact Us

    • Headquarters
    • See Our Locations

    • © 2025 Astellas Pharma Inc.
    • Privacy Center
    • Site Map
    • Accessibility
    • Terms of Use
    • Cookies Policy
    • Update Cookie Preferences

    This website is intended for a global audience. Location specific resources can be found here.

    close

    ©2025 Astellas Pharma Inc. or its affiliates. All trademarks are the property of their respective owners.